Caffeine as a Neuroprotective Adenosine Receptor Antagonist

Annals of Pharmacotherapy

Volumn 38, Issue 4, 2004, Pages 717-718

  Dall'Igna, Oscar P ^a   Souza, Diogo O ^a   Lara, Diogo R ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; CAFFEINE;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DIETARY INTAKE; NERVE DEGENERATION; NEUROPROTECTION; NOTE; PARKINSON DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR;

ALZHEIMER DISEASE; ANIMALS; CAFFEINE; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A;

EID: 1542429118     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D307     Document Type: Note

References (18)

1. 2A) antagonists in PD. Neurology 2002;58:1154-60.
2. Maia L, de Mendonca A. Does caffeine intake protect from Alzheimer's disease? Eur J Neurol 2002;9:377-82.
3. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51:83-133.
4. 2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001;21:RC143.
5. Prat G, Robledo P, Rubio A, Barbanoj M, Jane F, Casas M. Effects of sub-chronic combined treatment with pergolide and caffeine on contralateral rotational behavior in unilateral 6-hydroxydopamine-denervated rats. Brain Res 2000;868:376-9.
6. 2A receptor blockade of β-amyloid neurotoxicity. Br J Pharmacol 2003;138:1207-9.
7. 2A antagonists. J Neurosci 2003;23:5361-9.
8. Acquas E, Tanda G, Di Chiara G. Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naïve and caffeine-pretreated rats. Neuropsychopharmacology 2002;27:182-93.
9. Brice CF, Smith AP. Effects of caffeine on mood and performance: a study of realistic consumption. Psychopharmacology (Berl) 2002;164:188-92.
10. Riedel W, Hogervorst E, Leboux R, Verhey F, van Praag H, Jolles J. Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology (Berl) 1995;122:158-68.
11. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283:2674-9.
12. Xu K, Xu YH, Chen JF, Schwarzschild MA. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci Lett 2002;322:13-6.
13. Doraiswamy PM. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs 2002;16:811-24.
14. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002;59:223-7.
15. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604-12.
16. Birks J, Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 2003;(1):CD000442.
17. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.
18. Jack CR, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003;60:253-60.